

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: GIPAJFIROX

Page 1 of 3

| DOCTOR'S ORDERS | Ht | cm | Wt | kg | BSA_ | m² |
|--|-------------------------------|----------|------------|------------------|-----------------------|------------------------------|
| REMINDER: Please ensure drug allergies | and previous b | leomy | in are d | ocumented | on the | Allergy & Alert Form |
| DATE: To I | oe given: | | | Сус | le #: | |
| Date of Previous Cycle: | | | | | | |
| ☐ Delay treatment week(s) ☐ CBC & Diff day of treatment | | | | | | |
| May proceed with doses as written if within 72 or equal to 100 x 109/L | 2 hours ANC <u>gre</u> | eater th | an or eq | ual to 1.5 x | (10 ⁹ /L, | platelets greater than |
| Dose modification for: | Other T | _ | | | | |
| Proceed with treatment based on blood work from | | | | | | |
| PREMEDICATIONS: Patient to take own s | supply. RN/Phai | rmacist | to confir | m | | · |
| dexamethasone ☐ 8 mg or ☐ 12 mg (select IV premedication ordered) | ct one) PO 30 to | 60 min | utes prio | r to treatme | nt (omit | if below dexamethasone |
| and select ONE of the following: | | | | | | |
| aprepitant 125 mg PO 30 to 60 minut | es prior to treatn | nent on | Day 1, t | hen 80 mg | PO dail | y on Day 2 and 3 |
| ondansetron 8 mg PO 30 to 60 minut | es prior to treatr | nent | | | | |
| netupitant-palonosetron 300 mg-0.5 | mg PO 30 to 60 |) minut | es prior t | o treatment | | |
| ☐ Prophylactic atropine 0.3 mg subcutaned | ously 30 minutes | prior to | irinotec | an | | |
| For prior oxaliplatin hypersensitivity reaction 45 minutes prior to oxaliplatin: dexametha 30 minutes prior to oxaliplatin: diphenhyd in NS 100 mL over 15 minutes (Y-site com | sone 20 mg IV rAMINE 50 mg | in 50 m | | | | d famotidine 20 mg IV |
| NO ice chips | | | | | | |
| ☐ Other: | | | | | | |
| ** Have Hyperse | nsitivity Reacti | on Tray | / & Prote | ocol Availa | ble** | |
| TREATMENT: (Note – continued over | 2 pages) □ r | epeat i | n 2 weel | ks | | |
| All lines to be primed with D5W | | | | | | |
| oxaliplatin 85 mg/m² x BSA = mg | g | | | | | |
| ☐ Dose Modification:mg/m² | x BSA = | m | 3 | | | |
| IV in 250 to 500 mL D5W over 2 hours imm | ediately followe | d by | | | | |
| * | ** CONTINUED | ON PA | GE 2 *** | • | | |
| DOCTOR'S SIGNATURE: | | | | | | SIGNATURE: |
| | | | | | | 110. |
| | | | | | | UC: |



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: GIPAJFIROX

Page 2 of 3

| DATE: | | | | | | |
|--|--|-------------------|------------|--|--|--|
| TREATMENT: (Continued) | | | | | | |
| leucovorin 400 mg/m² x BSA = ☐ Dose Modification: ☐ IV in 250 mL D5W over 1 hou | mg mg/m² x BSA =mg r 30 minutes* | | | | | |
| OR | | | | | | |
| ☐ leucovorin 20 mg/m IV push | ² x BSA = mg | | | | | |
| irinotecan 150 mg/m² x BSA =mg Dose Modification:mg/m² x BSA =mg IV in 500 mL D5W over 1 hour 30 minutes* | | | | | | |
| * irinotecan and leucovorin may be infused at the same time by using a Y connector placed immediately before the injection site. | | | | | | |
| fluorouracil 2400 mg/m² x BSA = mg** Dose Modification: mg/m² x BSA = mg** IV over 46 hours in D5W to a total volume of 230 mL by continuous infusion at 5 mL/h via Baxter LV5 INFUSOR ** For 3000 to 5500 mg dose, select INFUSOR per dose range below (doses outside dose banding range are prepared as ordered): | | | | | | |
| Dose Banding Range | Dose Band INFUSOR (mg) | Pharmacist Initia | I and Date | | | |
| Less than 3000 mg | Pharmacy to mix specific dose | | | | | |
| 3000 to 3400 mg | 3200 mg | | | | | |
| 3401 to 3800 mg | 3600 mg | | | | | |
| 3801 to 4200 mg | 4000 mg | | | | | |
| 4201 to 4600 mg | 4400 mg | | | | | |
| 4601 to 5000 mg | 4800 mg | | | | | |
| 5001 to 5500 mg | 5250 mg | | | | | |
| Greater than 5500 mg | Pharmacy to mix specific dose | | | | | |
| | | | | | | |
| Counsel patient to obtain supply of loperamide and take 4 mg PO at first onset of diarrhea and then 2 mg PO q 2 h | | | | | | |
| until diarrhea free x 12 hours (may take 4 mg PO q 4 h during the night). atropine 0.3 subcutaneously prn. May repeat every 30 min to a maximum dose of 1.2 mg for early diarrhea, abdominal | | | | | | |
| cramps, rhinitis, lacrimation, diaphoresis or flushing. | | | | | | |
| DOCTOR'S SIGNATURE: | SIGNATURE: | | | | | |
| | | | UC: | | | |



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: GIPAJFIROX

Page 3 of 3

| DATE: | | | | | |
|---|------------|--|--|--|--|
| RETURN APPOINTMENT ORDERS | | | | | |
| Return in two weeks for Doctor and Cycle and and Last Cycle. Return in week(s). | | | | | |
| CBC & Diff, creatinine, total bilirubin, ALT prior to each cycle | | | | | |
| If clinically indicated: | | | | | |
| ☐ ECG ☐ CA 19-9 ☐ CEA | | | | | |
| 🔲 alkaline phosphatase 🔲 albumin 🔲 GGT 🔲 sodium 🔲 potassium | | | | | |
| ☐ random glucose ☐ HbA1c | | | | | |
| ☐ INR weekly ☐ INR prior to each cycle | | | | | |
| ☐ Other tests: | | | | | |
| ☐ If appropriate: G-CSF | | | | | |
| ☐ Book for PICC assessment / insertion per Centre process | | | | | |
| ☐ Book for IVAD insertion per Centre process | | | | | |
| ☐ Weekly nursing assessment for (specify concern): | | | | | |
| ☐ Consults: | | | | | |
| \square See general orders sheet for additional requests. | | | | | |
| DOCTOR'S SIGNATURE: | SIGNATURE: | | | | |
| | UC: | | | | |